theralase_logo_destroying_cancer.png
Theralase Releases Q222 Interim Financial Statements
August 29, 2022 19:45 ET | Theralase Technologies Inc.
TORONTO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
theralase_logo_destroying_cancer.png
Theralase Expands Intellectual Property Portfolio
June 28, 2022 07:00 ET | Theralase Technologies Inc.
TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
theralase_logo_destroying_cancer.png
Theralase® Research - One of the Top 10 Most Downloaded Papers
June 24, 2022 07:00 ET | Theralase Technologies Inc.
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
theralase_logo_destroying_cancer.png
Theralase® Phase Ib NMIBC Clinical Study Published
June 21, 2022 07:00 ET | Theralase Technologies Inc.
TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
theralase_logo_destroying_cancer.png
Theralase Releases Q122 Interim Financial Statements
May 30, 2022 17:53 ET | Theralase Technologies Inc.
TORONTO, May 30, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
theralase_logo_destroying_cancer.png
Theralase Release FY2021 Audited Financial Statements
April 29, 2022 21:11 ET | Theralase Technologies Inc.
TORONTO, April 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Bladder Cancer Detection Kit Market Size Worth USD 322 Million by 2027 at 11.17% CAGR - Report by Market Research Future (MRFR)
April 26, 2022 15:47 ET | WantStats Research and Media Pvt. Ltd.
New York, US, April 26, 2022 (GLOBE NEWSWIRE) -- Bladder Cancer Detection Kit Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Bladder Cancer...
22157.jpg
Global Immune Checkpoint Inhibitors Market to 2027 - Size, Share & Industry Trends Analysis Report
April 26, 2022 06:43 ET | Research and Markets
Dublin, April 26, 2022 (GLOBE NEWSWIRE) -- The "Global Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application (Lung Cancer, Bladder Cancer, Melanoma,...
theralase_logo_destroying_cancer.png
Theralase® Provides Update on Phase II Bladder Cancer Clinical Study
April 05, 2022 07:00 ET | Theralase Technologies Inc.
TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Vantage Market Research.png
Antibody Drug Conjugates (ADCs) Market Size to Reach USD 13.17 Billion by 2028 - Powered by Approval for Biologics License Applications – Vantage Market Research
February 15, 2022 04:39 ET | Vantage Market Research
WASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Antibody Drug Conjugates (ADCS) Market finds that granted accelerated approval for biologics...